Einar Ponten - Lipum AB Chief Officer
| LIPUM Stock | SEK 6.85 0.15 2.24% |
Insider
Einar Ponten is Chief Officer of Lipum AB
| Age | 62 |
| Phone | 46 9 03 40 34 30 |
| Web | https://www.lipum.se |
Lipum AB Management Efficiency
The company has return on total asset (ROA) of (0.9118) % which means that it has lost $0.9118 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (1.8072) %, meaning that it generated substantial loss on money invested by shareholders. Lipum AB's management efficiency ratios could be used to measure how well Lipum AB manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Renee AguiarLucander | Calliditas Therapeutics | 61 | |
| Per Andersson | XSpray Pharma AB | 56 | |
| Jakob Lic | Oncopeptides AB | 51 | |
| Kristina Luthman | Oncopeptides AB | N/A | |
| Annika MBA | Oncopeptides AB | 57 | |
| AnnaKarin Ekberg | XSpray Pharma AB | 57 | |
| Julie Silber | Alligator Bioscience AB | N/A | |
| MSc MSc | Oncopeptides AB | 53 | |
| Peter Nygren | Oncopeptides AB | 64 | |
| Marie Svensson | Alligator Bioscience AB | 59 | |
| MSc MD | Oncopeptides AB | N/A | |
| Sandra Frithiof | Calliditas Therapeutics | N/A | |
| Kerstin Hasselgren | XSpray Pharma AB | 62 | |
| Krassimir Mitchev | Calliditas Therapeutics | 64 | |
| AnnKristin BSc | Calliditas Therapeutics | 68 | |
| Pr MD | Oncopeptides AB | N/A | |
| Grald Jesson | XSpray Pharma AB | N/A | |
| Sren Bregenholt | Alligator Bioscience AB | 52 | |
| Sumeet MD | Alligator Bioscience AB | N/A | |
| Jonathan Schur | Calliditas Therapeutics | 70 | |
| Malin Carlsson | Alligator Bioscience AB | 55 | |
Management Performance
| Return On Equity | -1.81 | |||
| Return On Asset | -0.91 |
Lipum AB Leadership Team
Elected by the shareholders, the Lipum AB's board of directors comprises two types of representatives: Lipum AB inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Lipum. The board's role is to monitor Lipum AB's management team and ensure that shareholders' interests are well served. Lipum AB's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Lipum AB's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Pernilla Abrahamsson, Chief Officer | ||
| Associate Lindquist, CoFounder Research | ||
| Pr Hernell, CoFounder Director | ||
| Marina Norberg, Chief Officer | ||
| Einar Ponten, Chief Officer |
Lipum Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Lipum AB a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.81 | |||
| Return On Asset | -0.91 | |||
| Operating Margin | 117.68 % | |||
| Current Valuation | 98.1 M | |||
| Shares Outstanding | 7.65 M | |||
| Shares Owned By Insiders | 81.67 % | |||
| Shares Owned By Institutions | 8.14 % | |||
| Price To Book | 35.65 X | |||
| Price To Sales | 3,380 X | |||
| Gross Profit | (48.69 M) |
Pair Trading with Lipum AB
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Lipum AB position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Lipum AB will appreciate offsetting losses from the drop in the long position's value.Moving against Lipum Stock
| 0.54 | NDA-SE | Nordea Bank Abp | PairCorr |
| 0.51 | AZN | AstraZeneca PLC | PairCorr |
| 0.49 | INVE-A | Investor AB ser | PairCorr |
| 0.48 | INVE-B | Investor AB ser | PairCorr |
| 0.47 | ATCO-B | Atlas Copco AB | PairCorr |
The ability to find closely correlated positions to Lipum AB could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Lipum AB when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Lipum AB - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Lipum AB to buy it.
The correlation of Lipum AB is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Lipum AB moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Lipum AB moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Lipum AB can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Lipum AB. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Complementary Tools for Lipum Stock analysis
When running Lipum AB's price analysis, check to measure Lipum AB's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Lipum AB is operating at the current time. Most of Lipum AB's value examination focuses on studying past and present price action to predict the probability of Lipum AB's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Lipum AB's price. Additionally, you may evaluate how the addition of Lipum AB to your portfolios can decrease your overall portfolio volatility.
| Stocks Directory Find actively traded stocks across global markets | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments |